KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $3.0 billion.

  • Bristol Myers Squibb's Accumulated Depreciation & Amortization fell 6069.95% to $3.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year decrease of 6069.95%. This contributed to the annual value of $9.6 billion for FY2024, which is 163.93% down from last year.
  • Per Bristol Myers Squibb's latest filing, its Accumulated Depreciation & Amortization stood at $3.0 billion for Q3 2025, which was down 6069.95% from $2.0 billion recorded in Q2 2025.
  • Bristol Myers Squibb's Accumulated Depreciation & Amortization's 5-year high stood at $10.7 billion during Q4 2021, with a 5-year trough of $1.0 billion in Q1 2025.
  • In the last 5 years, Bristol Myers Squibb's Accumulated Depreciation & Amortization had a median value of $5.2 billion in 2022 and averaged $5.7 billion.
  • In the last 5 years, Bristol Myers Squibb's Accumulated Depreciation & Amortization soared by 771.09% in 2021 and then crashed by 6069.95% in 2025.
  • Bristol Myers Squibb's Accumulated Depreciation & Amortization (Quarter) stood at $10.7 billion in 2021, then decreased by 3.84% to $10.3 billion in 2022, then fell by 5.02% to $9.8 billion in 2023, then dropped by 1.64% to $9.6 billion in 2024, then crashed by 68.4% to $3.0 billion in 2025.
  • Its last three reported values are $3.0 billion in Q3 2025, $2.0 billion for Q2 2025, and $1.0 billion during Q1 2025.